Cascades Capital Asset Management’s AbbVie ABBV Stock Holding History

Cascades Capital Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.23M	Sell	5,673 -87	-2%	-$19.3K	0.52%	42
2025 Q4	$1.32M	Buy	5,760 +16	+0.3%	+$3.65K	0.55%	37
2025 Q3	$1.33M	Buy	5,744 +17	+0.3%	+$3.46K	0.59%	34
2025 Q2	$1.06M	Buy	5,727 +20	+0.4%	+$3.72K	0.55%	37
2025 Q1	$1.2M	Sell	5,707 -230	-4%	-$44.7K	0.65%	31
2024 Q4	$1.06M	Sell	5,937 -26	-0.4%	-$4.78K	0.56%	34
2024 Q3	$1.18M	Buy	+5,963	New	+$1.11M	0.65%	32

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cascades Capital Asset Management's ABBV Position: Q1 2026 in Review

Cascades Capital Asset Management reduced its AbbVie (ABBV) stake by 1.5% in Q1 2026, selling an estimated $19.3K and leaving 5,673 shares worth $1.23M. The position accounts for 0.52% of the portfolio, ranked #42.

Cascades Capital Asset Management first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.33M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Cascades Capital Asset Management held 5,673 shares of AbbVie worth $1.23M as of Q1 2026.
Cascades Capital Asset Management sold 87 AbbVie shares in Q1 2026, an estimated $19.3K.
AbbVie made up 0.52% of Cascades Capital Asset Management's portfolio in Q1 2026, its #42 holding.
Cascades Capital Asset Management first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
Cascades Capital Asset Management's AbbVie position peaked at $1.33M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cascades Capital Asset Management's 13F filing for Q1 2026, filed 15 May 2026.